AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn't In The Black
On August 11, Autolus Therapeutics (NASDAQ:AUTL) reported second-quarter results that finally showed the kind of growth investors had been waiting years to see.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | MAK Capital One Michael Kaufman | 33,621,487 | $53,794,379 | 7.54% | |
| 2. | Armistice Capital Steven Boyd | 15,000,000 | $24,000,000 | -6% | 0.29% |
| 3. | Laurion Capital Management Benjamin A. Smith | 3,316,626 | $5,306,602 | 0.14% | |
| 4. | Renaissance Technologies Jim Simons | 1,984,700 | $3,175,520 | -14% | 0% |
| 5. | Millennium Management Israel Englander | 1,224,818 | $1,959,709 | +499% | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.34 | 6,713 | $15,681.57 | 13,287 | 2026-09-02 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 20,485,611 | $32,776,978 | 0.1% | |
| 2. | 16,640,720 | $26,625,152 | 100% | |
| 3. | 9,500,000 | $15,200,000 | 2.39% | |
| 4. | 7,833,282 | $12,924,915 | 0.01% | |
| 5. | 4,447,910 | $7,116,656 | 0.15% |